Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies
Nherera, L., Marks, D., Minhas, Rubin, Thorogood, Margaret and Humphries, Steve E.. (2011) Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart, Vol.97 (No.1175). e1181. ISSN 1355-6037
WRAP_Thorogood_Nherera_at_al_Revised_final_230311.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Official URL: http://dx.doi.org/10.1136/hrt.2010.213975
Objective To estimate the probabilistic cost-effectiveness
of cascade screening methods in familial
hypercholesterolaemia (FH) from the UK NHS perspective.
Design Economic evaluation (cost utility analysis)
comparing four cascade screening strategies for FH:
Using low-density lipoprotein (LDL) cholesterol
measurements to diagnose affected relatives
(cholesterol method); cascading only in patients with
a causative mutation identiﬁed and using DNA tests to
diagnose relatives (DNA method); DNA testing combined
with LDL-cholesterol testing in families with no mutation
identiﬁed, only in patients with clinically deﬁned ‘deﬁnite’
FH (DNA+DFH method); DNA testing combined with
LDL-cholesterol testing in no-mutation families of both
‘deﬁnite’ and ‘probable’ FH patients (DNA+DFH+PFH).
A probabilistic model was constructed to estimate the
treatment beneﬁt from statins, with all diagnosed
individuals receiving high-intensity statin treatment.
Population A cohort of 1000 people suspected of
having FH aged 50 years for index cases and 30 years for
relatives, followed for a lifetime.
Main outcomes Costs, quality-adjusted life-years
(QALY) and incremental cost-effectiveness ratios (ICER).
Results The DNA+DFH+PFH method was the most
cost-effective cascade screening strategy. The ICER was
estimated at £3666/QALY. Using this strategy, of the
tested relatives 30.6% will be true positives, 6.3% false
positives, 61.9% true negatives and 1.1% false negatives.
Probabilistic sensitivity analysis showed that this
approach is 100% cost-effective using the conventional
benchmark for cost-effective treatments in the NHS of
between £20 000 and £30 000 per QALY gained.
Conclusion Cascade testing of relatives of patients with
DFH and PFH is cost-effective when using a combination
of DNA testing for known family mutations and
LDL-cholesterol levels in the remaining families. The
approach is more cost-effective than current primary
prevention screening strategies.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RA Public aspects of medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Library of Congress Subject Headings (LCSH):||Medical screening -- Cost effectiveness, Hypercholesteremia -- Diagnosis -- Cost effectiveness, Hypercholesteremia -- Diagnosis -- Evaluation|
|Journal or Publication Title:||Heart|
|Publisher:||B M J Group|
|Access rights to Published version:||Restricted or Subscription Access|
|Funder:||National Collaborating Centre for Primary Care (Great Britain) (NCCPC), National Institute for Health and Clinical Excellence (Great Britain) (NICE)|
Actions (login required)